This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.

Note: We can assist only if the medicine is unavailable in your country.”

DAURISMO (Glasdegib)

General Description

Daurismo (glasdegib) is a prescription medication used in combination with cytarabine to treat adults newly diagnosed with acute myeloid leukemia (AML).

Getting Daurismo (glasdegib) in India

Daurismo is approved in the U.S., Europe, and other countries, but it is not yet commercially available in India. However, eligible patients in India may access this important therapy through the Named Patient Program (NPP).

MitoGENE helps patients obtain Daurismo (glasdegib) legally and safely, in collaboration with their treating doctor. We assist with documentation, import coordination, and delivery—ensuring full compliance with Indian regulatory guidelines.

If you or a loved one needs Daurismo (glasdegib), MitoGENE is here to guide you through every step of the process.

Disease Indications:Leukemia

Manufacturer:Pfizer

Usage:Oral

Medicine Approved by:

  • U.S. Food and Drug Administration (FDA)
  • European Medicines Agency (EMA)
  • Health Canada

Available Dosage Form & Package:

  • 100 Mg – 30 Tablets per Box

Shipping:

Room Temperature Shipping.  Daurismois shipped under controlled room temperature conditions (15°C to 25°C) using standard logistics procedures.

What is Daurismo (glasdegib) used for?

Daurismo (glasdegib) is a hedgehog pathway inhibitor used alongside low-dose cytarabine to treat newly diagnosed acute myeloid leukemia (AML) in adults aged 75 and above, or those with health conditions that make them unsuitable for intensive chemotherapy.

It is available in tablet form with 25 mg or 100 mg of glasdegib.

How does Daurismo (glasdegib) work?

Glasdegib targets and blocks a protein called SMO, which plays a role in uncontrolled cancer cell growth. When SMO is overactive, cancer cells grow and resist treatment. By inhibiting SMO, Daurismo helps prevent cancer progression and makes chemotherapy more effective.

When used with chemotherapy, such as cytarabine, Daurismo helps eliminate cancer cells that may otherwise survive and grow after treatment.

Regulatory Approvals

Daurismo (glasdegib) has been approved for AML treatment by:

  • FDA (USA) – November 21, 2018
  • EMA (Europe) – June 26, 2020
  • Health Canada – June 12, 2020

(Availability may vary by country; please contact us for regional details.)

How is Daurismo taken?

The typical regimen includes:

  • 100 mg of Daurismo taken orally once daily.
  • Cytarabine 20 mg injected subcutaneously twice daily on days 1–10 of each 28-day cycle.

Tablets should be swallowed whole, with or without food, at the same time each day. Do not crush or split tablets.

Missed dose instructions:
If a dose is missed, take it as soon as possible (at least 12 hours before the next dose). Do not take two doses within 12 hours.

Important safety tip:
Avoid donating blood or blood products during treatment and for 30 days after the last dose.

Possible Side Effects

Common side effects (≥20% patients):

  • Anemia
  • Fatigue
  • Nausea
  • Bleeding
  • Fever with low white blood cell count
  • Muscle pain
  • Appetite loss
  • Swelling in limbs
  • Taste changes
  • Rash
  • Mouth sores
  • Constipation

Serious side effects:

  • Heart rhythm changes (QTc prolongation)

Use in Special Populations

Pregnancy Warning:
Daurismo may cause serious harm to unborn babies. Effective contraception is required during treatment and for:

  • Women: At least 30 days after the final dose
  • Men: At least 4 months after the final dose

Breastfeeding is not recommended during and for 30 days after treatment.

Before starting Daurismo, inform your doctor if you:

  • Are pregnant or planning pregnancy
  • Have heart issues, especially long QT syndrome
  • Have abnormal electrolyte levels
  • Are taking other medications

Always consult your doctor for personalized medical advice and dosage adjustments.

References

1. Full prescribing information [FDA]: Daurismo (glasdegib) [PDF]
Pfizer, Nov 2018

2. Daurismo Patient Brochure
Pfizer, cited Sep 2021

3. FDA approves new treatment for patients with acute myeloid leukemia
FDA, Nov 2018

4. Daurismo
EMA Jun 2020

5. Health Canada Approval of Daurismo (glasdegib)
Pfizer, Jun 2020

How to Access Daurismo (glasdegib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)

If Daurismo is not yet approved or available commercially in India, MitoGENE can help you access it through a legal pathway. Here’s how:

    Upload Prescription

    Upload Patient Consent Form

    Patient Consent Form
    Download

    Please download and complete this form, including your signature, and attach it to the request form or email it to info@mitogene.org along with the patient details.